Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
Arshad M Khanani,Sunil S Patel,Giovanni Staurenghi,Ramin Tadayoni,Carl J Danzig,David A Eichenbaum,Jason Hsu,Charles C Wykoff,Jeffrey S Heier,David R Lally,Jordi Monés,Jared S Nielsen,Veeral S Sheth,Peter K Kaiser,Julie Clark,Liansheng Zhu,Hersh Patel,Justin Tang,Dhaval Desai,Glenn J Jaffe,GATHER2 trial investigators,Arturo Alezzandrini,Anibal Andres Francone,Joaquín Bafalluy,Silvina Bainttein,Jose Luna Pinto,Mario Saravia,Matko Vidosevich,Carlos Zeolite,Federico Furno Sola,Andrew Chang,Elisa Eleanor Guida Cornish,Thanh Nguyen,Oliver Findl,Anton Haas,Martina Kralinger,Stefan Sacu,Laurence Dominique Postelmans,Michel Farah,Mauricio Maia,Marcio Nehemy,Fareed Ali,Michael Brent,Michael Dollin,John Gonder,Amin Kherani,Andrew Merkur,Raman Tuli,Monica Marie Lopera,Francisco Rodriguez,Mario Bradvica,Jan Ernest,Kuldar Kalijurand,Kai Noor,Yves Cohen,Catherine Creuzot-Garcher,Flore De Bats,François Devin,Catherine Français-Maury,Laurent Kodjikian,Jean François Korobelnik,Yannick Le Mer,Maddalena Quaranta El Maftouhi,Sam Razavi,Eric Souied,Michel Weber,Nicole Eter,Nicolas Feltgen,Salvatore Grisanti,Peter Walter,Raffael Liegl,Katrin Lorenz,Georg Spital,Siegfried Priglinger,Martin Spitzer,Michael Volker,Tim Krohne,Claudia Jochmann,Chris Patrick Lohmann,Carsten Framme,Agnes Kerenyi,Andras Papp,Andras Seres,Edit Toth-Molnar,Alexis Tsorbatzoglou,Atilla Vajas,Balázs Varsanyi,Gabor Vogt,Asaf Bar,Eva Eting,David Hauser,Jamie Levy,Nurit Mathalone,Haia Morori-Katz,Irit Rosenblatt,Shiri Soudry-Zayit,Omert Trivizky,Francesco Bandello,Antonio Pasquale Ciardella,Michele Figus,Fabrizio Giansanti,Paolo Lanzetta,Cesare Mariotti,Leonardo Mastropasqua,Edoardo Midena,Francesco Parmeggiani,Federico Ricci,Francesca Simonelli,Francesco Viola,Monica Varano,Guna Laganovska,Sławomir Cisiecki,Wojciech Jedrzejewski,Jakub Kaluzny,Marta Misiuk-Hojło,Santiago Abengoechea,Javier Araiz Iribarren,Franciso Javier Ascaso,Juan Manuel Cubero,Roberto Gallego-Pinazo,Francisco Gomez-Ulla De Irazazabal,Ignasi Jürgens Mestre,Jordi Manel Mones I Carilla,Javier Montero Moreno,José María Ruiz Moreno,Laura Sararols Ramsay,Alfredo Garcia Layana,Louise Downey,Prema Abraham,Daniel Virgil Alfaro,Nika Bagheri,Irene Barbazetto,Joseph Benevento,Paul Bernstein,George Bertolucci,Abdhish Bhavsar,William Bridges,Harold Logan Brooks Jr,Jamin Brown,Alexander Brucker,Charles M Calvo,Antonio Capone,John Carlson,Clement Chan,Emmanuel Chang,Brian Chan-Kai,Nauman Chaudhry,Sanford Chen,Karl Csaky,Howard Cummings,Carl Danzig,Amr Dessouki,David Dyer,Alexander Eaton,David Eichenbaum,David Faber,Robert Feldman,Neil Finnen,William Freeman,Ronald Frenkel,Christine Gonzales,Victor Gonzalez,John Gross,Sunil Gupta,Edward Hall,Min-Kyu Han,Jeffrey Heier,Vrinda Hershberger,Patrick Higgins,Michael Ip,Eric Jablon,Brian Jewart,Vishak John,Jonathan Jonisch,Brian Joondeph,Christine Kay,Arshad Khanani,Gregg T Kokame,Robert Kwun,Michael Lai,David Lally,Ketan Laud,Adrian Lavina,Michael Lee,Phoebe Lin,Haijiang Lin,Niranjan Manoharan,Dennis Marcus,Adam Martidis,Frank McCabe,Jared Nielsen,James Osher,James Palmer,Sunil Patel,Joel Pearlman,Stephen Perkins,Ashkan Pirouz,Jawad Qureshi,John Randolph,Niloofar Piri,Phillip Rosenfeld,David Saperstein,Richard Scartozzi,Steven Schwartz,Ashish Sharma,Atul Sharma,Veeral Sheth,Michael Singer,David Spinak,Eric Suan,Homayoun Tabandeh,Ali Tabassian,Eduardo Uchiyama,Michael Varenhorst,Alan Wagner,David Warrow,John Wells Iii,Robert Wong,Keye Wong,Charles Wykoff,Samantha Xavier,Edward Ysasaga
DOI: https://doi.org/10.1016/S0140-6736(23)01583-0
2023-10-21
Abstract:Background: Geographic atrophy is an advanced form of dry age-related macular degeneration that can lead to irreversible vision loss and high burden of disease. We aimed to assess efficacy and safety of avacincaptad pegol 2 mg in reducing geographic atrophy lesion growth. Methods: GATHER2 is a randomised, double-masked, sham-controlled, 24-month, phase 3 trial across 205 retina clinics, research hospitals, and academic institutions globally. To be eligible, patients had to be aged 50 years or older with non-centrepoint-involving geographic atrophy and best corrected visual acuity between 20/25 and 20/320 in the study eye. Eligible patients were randomly assigned (1:1) to monthly avacincaptad pegol 2 mg administered as a 100 μL intravitreal injection or sham for the first 12 months. Randomisation was performed using an interactive response technology system with stratification by factors known to be of prognostic importance in age-related macular degeneration. Patients, investigators, study centre staff, sponsor personnel, and data analysts were masked to treatment allocation. The primary endpoint was geographic atrophy lesion size measured by fundus autofluorescence at baseline, month 6, and month 12. Efficacy and safety analyses were done in the modified intention-to-treat and safety populations, respectively. This trial is registered with ClinicalTrials.gov, NCT04435366. Findings: Between June 22, 2020, and July 23, 2021, 1422 patients were screened for eligibility, of whom 448 were enrolled and randomly assigned to avacincaptad pegol 2 mg (n=225) or sham (n=223). One patient in the sham group did not receive study treatment and was excluded from analyses. There were 154 (68%) female patients and 71 (32%) male patients in the avacincaptad pegol 2 mg group, and 156 (70%) female patients and 66 (30%) male patients in the sham group. From baseline to month 12, the mean rate of square-root-transformed geographic atrophy area growth was 0·336 mm/year (SE 0·032) with avacincaptad pegol 2 mg and 0·392 mm/year (0·033) with sham, a difference in growth of 0·056 mm/year (95% CI 0·016-0·096; p=0·0064), representing a 14% difference between the avacincaptad pegol 2 mg group and the sham group. Ocular treatment-emergent adverse events in the study eye occurred in 110 (49%) patients in the avacincaptad pegol 2 mg group and 83 (37%) in the sham group. There were no endophthalmitis, intraocular inflammation, or ischaemic optic neuropathy events over 12 months. To month 12, macular neovascularisation in the study eye occurred in 15 (7%) patients in the avacincaptad pegol 2 mg group and nine (4%) in the sham group, with exudative macular neovascularisation occurring in 11 (5%) in the avacincaptad pegol 2 mg group and seven (3%) in the sham group. Interpretation: Monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth over 12 months than sham treatment, suggesting that avacincaptad pegol might slow disease progression and potentially change the trajectory of disease for patients with geographic atrophy. Funding: Iveric Bio, An Astellas Company.